445 Marine View Avenue
Suite 320
Del Mar, CA 92014
United States
(858) 925-7000
https://www.lenz-tx.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Evert B. Schimmelpennink | President, CEO, Secretary & Director | 886,54k | N/A | 1972 |
Mr. Shawn Olsson | Chief Commercial Officer | 532,13k | N/A | 1983 |
Mr. Marc G. Odrich M.D. | Chief Medical Officer | 576,95k | N/A | 1959 |
Mr. James W. McCollum | Co-Founder & Director | N/A | N/A | 1955 |
Mr. Gerald Horn | Senior Scientific Advisor & Founder | N/A | N/A | N/A |
Mr. Daniel R. Chevallard CPA | Chief Financial Officer | N/A | N/A | 1980 |
Mr. Domenick Porfidia | Vice President of Sales | N/A | N/A | N/A |
Mr. David Murphy | Senior Director of Marketing & Alliance Development | N/A | N/A | N/A |
Mr. Marvin J. Garrett | Senior Vice President of Regulatory & Quality | N/A | N/A | 1951 |
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
LENZ Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 8. Die grundlegenden Scores sind Audit: 9, Vorstand: 5, Shareholderrechte: 8, Kompensation: 9.